D-Penicillamine administration and the incidence of retinopathy of prematurity

Journal of Perinatology

Volumn 27, Issue 2, 2007, Pages 103-111

  Christensen, R D ^a   Alder, S C ^b   Richards, S C ^a   Lambert, D K ^a   Schmutz, N ^a   Wiedmeier, S E ^b   Burnett, J ^b   Baer, V L ^a   Horn, J T ^a   Richards, M ^a   Barraza, J ^a  

^a McKay Dee Hospital Center   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; HEMOGLOBIN; INOSITOL; IRON OXIDE; LACTOSE; MAGNESIUM STEARATE; OXYGEN; PENICILLAMINE; TITANIUM DIOXIDE;

ARTICLE; BILIRUBIN BLOOD LEVEL; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG FORMULATION; ERYTHROCYTE TRANSFUSION; FEMALE; GESTATIONAL AGE; GROWTH RATE; HEMOGLOBIN DETERMINATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFANT; LABORATORY TEST; LASER SURGERY; MALE; NEUTROPENIA; NEWBORN; NEWBORN INTENSIVE CARE; OPEN STUDY; OXYGEN SUPPLY; PREMATURITY; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; SUSPENSION; THROMBOCYTOPENIA;

BILIRUBIN; CHELATING AGENTS; CREATININE; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; NEUTROPENIA; OXYHEMOGLOBINS; PENICILLAMINE; RETINOPATHY OF PREMATURITY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33846704161     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211653     Document Type: Article

References (35)

1. Christensen RD, Alder SC, Richards SC, Horn JT, Lambert DK, Baer VL. A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. J Perinatol 2006; 26: 120-124.
2. Phelps DL, ETROP Cooperative Group. The early treatment for retinopathy of prematurity study: Better outcomes, changing strategy. Pediatrics 2004; 114: 490-491.
3. Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: Screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005; 90: F240-F244.
4. http://www.nei.nih.gov/health/rop/index.asp.
5. Aiello LP. Vascular endothelial growth factor and the eye - past, present, and future. Arch Ophthalmol 1996; 114: 1252-1254.
6. Aiello LP. Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 1997; 38: 1647-1652.
7. Polytarchou C, Papadimitriou E. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radic Res 2004; 38: 501-508.
8. Stone JS, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002; 9: 231-238.
9. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxide. Mol Cell Biochem 2004; 264: 85-97.
10. Hunt JT, Lee VG, Liu ECK et al. Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Int J Peptide Protein Res 1993; 42: 249-258.
11. Matsubara T, Saura R, Hirohata K. Inhibition of human endothelial cell proliferation in vitro and neovasularization in vivo by D-penicillamine. J Clin Invest 1989; 83: 158-167.
12. Yoshida D, Ikeda Y, Nakazawa S. Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995; 37: 287-292.
13. Pietraforte D, Mallozzi C, Scorza G, Minetti M. Role of thiols in the targeting of S-nitroso thiols to red blood cells. Biochemistry 1995; 34: 7177-7185.
14. McBrien NA, Norton TT. Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Exp Eye Res 1994; 59: 475-486.
15. Siemeister G, Schnurr B, Mohrs K, Schachtele C, Marme D, Martiny-Baron G. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun 1996; 222: 249-255.
16. Lakatos L, Kover B, Oroszlan GY, Vekerdy ZS. Penicillamine therapy in ABO hemolytic disease of the newborn infant. Eur J Pediatr 1976; 123: 133-137.
17. Lakatos L, Hatvani I, Oroszlan G, Balla G, Karmazsin L, Alaka O et al. Controlled trial of D penicillamine to prevent retinopathy of prematurity. Acta Paediatr Hungar 1986; 27: 47-56.
18. Phelps DL, Lakatos L, Watts JL. -Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2001; (1): CD001073.
19. Lambert DK, Ercal N, Richards SC, Veng-Peterson P, Horn JT, Richards M et al. Pharmacokinetics Of D-penicillamine after enteral administration to preterm neonates. Submitted for publication 2006.
20. z0 An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 2005; 123: 991-995.
21. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome - structure and function. Arch Ophthalmol 1990; 108: 1408-1416.
22. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity - results of the ETROP randomized trial. Arch Ophthalmol 2003; 121: 1684-1696.
23. Gilbert C, Fielder A, Gordillo L, Guinn G, Semiglia R, Visintin P et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implication for screening programs. Pediatrics 2005; 115: E518-e525.
24. Phelps DL, Watts JL. Early light reduction to prevent retinopathy of prematurity in very low birth weight infants In: Cochrane Database Syst Rev. 2001; (1) CD 000122.
25. STOP-ROP Multicenter Trial. Supplemental therapeutic oxygen for prethrehold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 2000; 105: 295-310.
26. Saugstad OD. Oxygen for newborns: How much is too much? J Perinatol 2005; 25(Suppl 2): S45-S49.
27. Friedman CA, McVey J, Borne MJ, James M, May WL, Temple DM et al. Relationship between serum inositol concentration and development of retinopathy of prematurity: A prospective study. J Pediatr Ophthalmol Strabismus 2000; 37: 79-86.
28. Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2003; (4): CD000366.
29. Flynn JT, Chan-Ling T. Retinopathy of prematurity: Two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 2006; 142: 46-59.
30. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: Correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 2004; 79: 623-630.
31. May CA, Ohlmann AV, Hammes H, Spandau UH. Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy. Exp Eye Res 2006; 82: 341-348.
32. Jensen L, Schjerling P, Hellsten Y. Regulation of VEGF and bFGF mRNA expression and other proliferative compounds in skeletal muscle cells. Angiogenesis 2004, 7: 255-267.
33. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209-221.
34. Drosos AA, Geogriou P, Politi EN, Voulgori PV. -penicillamine in early rheumatoid arthritis. Clin Exp Rheumatol 1997; 15: 580-581.
35. Vekerdy-Lakatos S, Lakatos L, Oroszlan G, Itzes B. One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period. Acta Paediatr Hung 1987; 28: 9-16.